Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results

Stock Information for Guided Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Guided Therapeutics Inc

Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation
Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings
Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial
Guided Therapeutics Makes Initial Shipment to New Chinese Distribution Partner Hangzhou Dongye Medical Technology, Ltd.
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
Guided Therapeutics Receives $100,000 from SMI's Investment Partners to Continue Commercialization Process of LuViva in China
Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables
Guided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in China

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.